Cristina Cristofoletti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9041697/publications.pdf

Version: 2024-02-01

933447 24 366 10 citations h-index papers

g-index 24 24 24 819 docs citations times ranked citing authors all docs

996975

15

#	Article	IF	CITATIONS
1	Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis. Journal of Investigative Dermatology, 2022, 142, 3009-3019.e9.	0.7	4
2	Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome. Cancers, 2022, 14, 2847.	3.7	1
3	Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-CellÂLymphoma. Journal of Investigative Dermatology, 2020, 140, 1045-1053.e6.	0.7	19
4	The Interplay between CD27dull and CD27bright B Cells Ensures the Flexibility, Stability, and Resilience of Human B Cell Memory. Cell Reports, 2020, 30, 2963-2977.e6.	6.4	76
5	A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders. Genes and Immunity, 2020, 21, 131-135.	4.1	11
6	Loss of \hat{l}^2 -arrestin-2 gene and possible functional consequences on Sezary Syndrome. Cell Cycle, 2019, 18, 1292-1294.	2.6	2
7	Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance. Leukemia, 2019, 33, 1231-1242.	7. 2	28
8	Abstract 3912: The PI3K/mTOR dual inhibitor PF-04691502 shows antitumor activity in Sezary cells and in a xenograft mouse model. , 2019, , .		1
9	Sézary Syndrome, recent biomarkers and new drugs. Chinese Clinical Oncology, 2019, 8, 2-2.	1.2	13
10	DEC1/STRA13 is a key negative regulator of activation-induced proliferation of human B cells highly expressed in anergic cells. Immunology Letters, 2018, 198, 7-11.	2.5	11
11	Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome. Cell Death and Disease, 2018, 9, 1178.	6.3	10
12	T Cell Leukemia/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1. PLoS ONE, 2018, 13, e0204775.	2.5	5
13	Abstract 761: The role of PI3 kinase pathway in the the skin of Sezary syndrome. , 2018, , .		О
14	Abstract 936: Skin microenvironment enhances proliferation index and activates mTORC 1 signaling in sezary syndrome. , 2016, , .		0
15	Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: The yin and yang of HCV-driven lymphoproliferation and autoimmunity. Autoimmunity Reviews, 2013, 12, 430-435.	5.8	30
16	Comprehensive analysis of PTEN status in Sézary syndrome. Blood, 2013, 122, 3511-3520.	1.4	47
17	Clonal B cells of HCVâ€associated mixed cryoglobulinemia patients contain exhausted marginal zoneâ€like and CD21 ^{low} cells overexpressing Stra13. European Journal of Immunology, 2012, 42, 1468-1476.	2.9	40
18	Abstract 4178: Tcl1 enhances keratinocytes' survival/proliferation by promoting erk and jnk/sap phosphorylation at the expense of p38 and by controlling c-fos expression through miR-29b and miR-181a-1., 2012, , .		0

#	Article	IF	CITATIONS
19	Gistic Evaluation in Sezary Syndrome. Blood, 2012, 120, 4814-4814.	1.4	O
20	Anayisis of Chromosomal Alterations by Array-Based Comparative Genomic Hybridization in 25 Patients with Selzary Syndrome Blood, 2012, 120, 2714-2714.	1.4	0
21	Abstract 150: Regulation of TGFB receptor by miR21 in Sezary syndrome. , 2011, , .		O
22	Identification of Key Regions and Genes Important in the Pathogenesis of Sézary Syndrome by Combining Genomic and Expression Microarrays. Cancer Research, 2009, 69, 8438-8446.	0.9	68
23	The TCL1 Gene Is Involved, Other Than in Lymphoid Differentiation and Early Embryogenesis, Also in the Development of the Hair Follicle Blood, 2005, 106, 4390-4390.	1.4	O
24	SDF-1-CXCR4 Signaling and Downregulation of CD26/Dipeptidyl-Peptidase IV Are Involved in Skin-Homing of Sezary Cells Blood, 2005, 106, 4489-4489.	1.4	0